Selected article for: "excessive inflammatory response and inflammatory response"
Author: Sagris, Marios; Theofilis, Panagiotis; Antonopoulos, Alexios S.; Tsioufis, Costas; Oikonomou, Evangelos; Antoniades, Charalambos; Crea, Filippo; Kaski, Juan Carlos; Tousoulis, Dimitris
Title: Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives
  • Cord-id: mlaxohxm
  • Document date: 2021_6_21
    • ID: mlaxohxm
    Snippet: Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This revi
    Document: Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomodulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • abdominal pain and acute coagulopathy: 1
    • abdominal pain and acute inflammatory response: 1
    • abdominal pain and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • abdominal pain and acute myocardial injury: 1
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute phase protein: 1
    • abdominal pain and acute phase protein increase: 1
    • abdominal pain and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • abdominal pain and admission month: 1
    • abdominal pain and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • abdominal pain and low certainty: 1
    • abdominal pain and low density: 1, 2
    • abdominal pain and low density lipoprotein: 1
    • abdominal pain and low mortality: 1, 2
    • abdominal pain and low mortality rate: 1, 2
    • abdominal pain and lung damage: 1
    • abdominal pain and macrophage activation: 1, 2, 3, 4
    • abdominal pain and macrophage activation syndrome: 1, 2, 3, 4